Home » Stocks » Alpine Immune Sciences

Alpine Immune Sciences, Inc. (ALPN)

Stock Price: $8.01 USD 0.00 (0.00%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 190.52M
Revenue (ttm) 2.95M
Net Income (ttm) -33.08M
Shares Out 23.78M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $8.01
Previous Close $8.01
Change ($) 0.00
Change (%) 0.00%
Day's Open 8.01
Day's Range 7.81 - 8.34
Day's Volume 33,767
52-Week Range 2.05 - 15.00

More Stats

Market Cap 190.52M
Enterprise Value 122.24M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 23.78M
Float 12.61M
EPS (basic) -1.78
EPS (diluted) -1.78
FCF / Share 1.49
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 14.54%
Payout Ratio n/a
Shares Short 26,841
Short Ratio 0.41
Short % of Float 0.21%
Beta 1.55
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 6.88
PS Ratio 64.54
PB Ratio 12.78
Revenue 2.95M
Operating Income -34.04M
Net Income -33.08M
Free Cash Flow 27.70M
Net Cash 68.28M
Net Cash / Share 2.87
Gross Margin -1,155.39%
Operating Margin -1,153.25%
Profit Margin -1,120.50%
FCF Margin 938.48%
ROA -24.63%
ROE -107.30%
ROIC -89.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.50*
(168.41% upside)
Low
18.0
Current: $8.01
High
27.0
Target: 21.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue1.740.711.732.950.49---
Revenue Growth146.81%-59.27%-41.32%499.59%----
Gross Profit1.740.711.732.950.49---
Operating Income-43.57-36.63-14.97-1.19-0.37-14.49-15.28-8.88
Net Income-41.85-36.49-7.78-1.23-0.37-14.66-16.20-9.57
Shares Outstanding18.3613.856.480.560.500.180.040.03
Earnings Per Share-2.28-2.63-1.20-2.18-0.74-81.08-418.00-278.80
Operating Cash Flow-35.35-28.42-16.57-3.804.82-14.45-14.29-9.52
Capital Expenditures-0.82-0.50-0.59-0.78-0.01--0.13-0.03
Free Cash Flow-36.17-28.91-17.16-4.584.81-14.45-14.42-9.55
Cash & Equivalents40.6552.3081.3711.8287.2527.813.60-
Total Debt16.364.205.030.11--15.34-
Net Cash / Debt24.3048.1076.3411.7187.2527.81-11.75-
Assets54.0954.8785.2212.6087.9128.544.13-
Liabilities24.6210.286.312.524.4244.3017.63-
Book Value29.4744.5978.92-1.4683.49-15.75-91.29-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Alpine Immune Sciences, Inc.
Country United States
Employees 53
CEO Mitchell H. Gold

Stock Information

Ticker Symbol ALPN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALPN

Description

Alpine Immune Sciences focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.